{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:05:08Z","timestamp":1785387908680,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen Pharma SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.euo.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T15:11:27Z","timestamp":1739027487000},"page":"1474-1485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Laurence","family":"Albiges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Gross-Goupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Bedke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rio","family":"Fontes-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Rottey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.01.007_b0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1634\/theoncologist.2017-0534","article-title":"Second-line treatment landscape for renal cell carcinoma: a comprehensive review","volume":"23","author":"Tannir","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2025.01.007_b0010","first-page":"179","article-title":"Renal cell carcinoma: diagnosis and management","volume":"99","author":"Gray","year":"2019","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.euo.2025.01.007_b0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.01.007_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2025.01.007_b0030","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.semradonc.2021.02.002","article-title":"Stereotactic ablative radiation (SAbR) for oligometastatic RCC","volume":"31","author":"All","year":"2021","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0040","article-title":"State of the art: multidisciplinary management of oligometastatic renal cell carcinoma","volume":"43","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2025.01.007_b0045","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0895-4356(03)00211-7","article-title":"Delphi as a method to establish consensus for diagnostic criteria","volume":"56","author":"Graham","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.euo.2025.01.007_b0050","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2023.02.015","article-title":"Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe","volume":"185","author":"Kroese","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.01.007_b0055","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1177\/0269216317690685","article-title":"Guidance on Conducting and Reporting Delphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review","volume":"31","author":"J\u00fcnger","year":"2017","journal-title":"Palliat Med"},{"key":"10.1016\/j.euo.2025.01.007_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.techfore.2020.120484","article-title":"Consensus in the Delphi method: what makes a decision change?","volume":"163","author":"Barrios","year":"2021","journal-title":"Technol Forecast Soc Change"},{"key":"10.1016\/j.euo.2025.01.007_b0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0070","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.3390\/cancers14194607","article-title":"Determining front-line therapeutic strategy for metastatic clear cell renal cell carcinoma","volume":"14","author":"Zarrabi","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.01.007_b0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41585-022-00676-0","article-title":"Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma","volume":"20","author":"Rosellini","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.01.007_b0080","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/S1470-2045(24)00023-8","article-title":"Delphi consensus on stereotactic ablative radiotherapy for oligometastatic and oligoprogressive renal cell carcinoma-a European Society for Radiotherapy and Oncology study endorsed by the European Association of Urology","volume":"25","author":"Marvaso","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0085","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/cncr.33490","article-title":"Increasing the evidence for surveillance of metastatic renal cancer","volume":"127","author":"Bex","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.01.007_b0090","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0100","article-title":"SABR for oligometastatic renal cell carcinoma","volume":"45","author":"David","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0105","doi-asserted-by":"crossref","first-page":"17822","DOI":"10.1038\/s41598-021-97365-6","article-title":"The prognosis and clinicopathological features of different distant metastases patterns in renal cell carcinoma: analysis based on the SEER database","volume":"11","author":"Wei","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2025.01.007_b0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.01.007_b0115","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jamaoncol.2021.4544","article-title":"Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma","volume":"7","author":"Hirsch","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0120","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2025.01.007_b0125","doi-asserted-by":"crossref","first-page":"S1024","DOI":"10.1016\/j.annonc.2023.09.1133","article-title":"1903P\u2003Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): post hoc analysis of the CLEAR trial","volume":"34","author":"Gruenwald","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0130","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cancers15030793","article-title":"Complete response in metastatic clear cell renal cell carcinoma patients treated with immune-checkpoint inhibitors: remission or healing? How to improve patients\u2019 outcomes?","volume":"15","author":"Thouvenin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2025.01.007_b0135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.01.007_b0140","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.01.007_b0145","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.01.007_b0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0155","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.euo.2025.01.007_b0160","doi-asserted-by":"crossref","first-page":"S1263","DOI":"10.1016\/j.annonc.2024.08.2318","article-title":"LBA75\u2003Prospective randomised phase-II trial of ipilimumab\/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial","volume":"35","author":"Bergmann","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0165","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.01.007_b0170","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.01.007_b0175","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.eururo.2023.07.006","article-title":"Patient-reported outcome measurement and reporting for patients with advanced renal cell carcinoma: a systematic literature review","volume":"84","author":"Motzer","year":"2023","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:41:07Z","timestamp":1778143267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2588931125000288"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a Consensus on the Management of Metastatic Renal Cell Carcinoma: Insights from a European Delphi Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}